MATERNAL DRUG USE AND INFANT CONGENITAL MALFORMATIONS

Background
Maternal use of antacids or drugs for GERD and infant congenital malformations
Maternal use of drugs for intestinal problems, except intestinal inflammations, and infant congenital malformations
Maternal use of drugs for inflammatory intestinal disease and infant congenital malformations
Maternal use of anti-obesity drugs and infant congenital malformations
Maternal use of insulin or oral hypoglycemic drugs and infant congenital malformations
Maternal use of vitamins and infant congenital malformations
Maternal use of anticoagulants and hemostatic drugs and infant congenital malformations
Maternal use of drugs for cardiovascular diseases and infant congenital malformations
Maternal use of dermatological drugs and infant congenital malformations
Maternal use of prolactin inhibitors or sex hormones and infant congenital malformations
Maternal use of drugs for thyroid disease and infant congenital malformations
Maternal systemic use of corticosteroids and infant congenital malformations
Maternal use of hypophyseal or hypothalamic hormones and infant congenital malformations
Maternal use of antibacterial or antifungal drugs and infant congenital malformations
Maternal use of antiviral drugs, immunoglobulins, or vaccines and infant congenital malformations
Maternal use of cytostatic/cytotoxic drugs or endocrine drugs used for malignancy and infant congenital malformations
Maternal use of immunostimulating or immunosuppressive drugs and infant congenital malformations
Maternal use of NSAID drugs and infant congenital malformations
Maternal use of drugs other than NSAIDs for musculoskeletal diseases and infant congenital malformations
Maternal use of opiates or opioid analgesics and infant congenital malformations
Maternal use of mild analgesics and infant congenital malformations
Maternal use of drugs for migraine and infant congenital malformations
Maternal use of anticonvulsants and infant congenital malformations
. Maternal use of antipsychotics and infant congenital malformations
Maternal use of sedatives or hypnotics and infant congenital malformations
Maternal use of antidepressants and infant congenital malformations
Maternal use of other psychoactive drugs and infant congenital malformations
Maternal use of antiprotozoans, antihelminthics or insecticides and infant congenital malformations
Maternal use of nasal decongestants, other nasal preparations, or throat preparations and infant congenital malformations
Maternal use of anti-asthmatics and infant congenital malformations
Maternal use of cough and common cold medicines and infant congenital malformations
Maternal use of drugs for nausea and vomiting in pregnancy and infant congenital malformations
Maternal use of antihistamine drugs for allergy and infant congenital malformations
Maternal use of local eye and ear drug therapy and infant congenital malformations
Maternal use of some groups of drugs with common side effects and infant congenital malformations
The practical consequences of observed associations between the use of drug and infant congenital malformation.

This book is the combination of the literature on maternal drug use and birth defects with a set of new data on most types of drugs.
In this book, for each group of drugs the relevant scientific literature on drug teratogenicity is presented, with consideration of possible sources of error and also what the findings may mean from a practical point of view. The book also adds data from the Swedish health registers for 1996-2013 based on more than 1.7 million early-pregnancy midwife interviews.
Maternal Drug Use and Infant Congenital Malformations will find an engaged audience among people working within the field, and will be of interest to healthcare providers, especially obstetricians and other clinicians who treat women of childbearing age.

Features
• Features the unique combination of detailed literature evaluation and presentation of new data
• Focuses on research experiences since the 1960s within the field
• Includes tables and diagrams that present details of the findings, which can be useful for researchers in the field

Author
Bengt Källén, MD, PhD, is professor emeritus of the Tornblad Institute at Lund University in Lund, Sweden. Dr. Källén has been professor in embryology since 1965, was head of the Tornblad Institute from 1965-2017, and served as a consultant at the National Board of Health and Welfare in Stockholm from 1964-2015. He has published about 400 scientific articles, many of which concern drug use during pregnancy, and a number of books.